Abstract 13P
Background
The limit of detection (LoD) represents the minimum number of reads to detect a variant in a given depth, especially in multigene panel testing (MGPT). The reliability of MGPT depends on LoD in detecting somatic variants with precision. Comparison based LoD calculations require multiple inputs like population and non-tumorous data, which needs a high computational power. The standard MGPTs calculate in-run LoD rather than allele specific. Here, we aim to introduce a single-data-driven parallelized algorithm that overcomes these limitations.
Methods
The algorithm utilizes VCF and BAM files and derives the log-odds score from the binomial probabilities of true positive and false positive along with the variant allele fraction. Subsequently, the algorithm determines the minimum VAF threshold, indicating that the variant is confidently detectable above the specified error rate (default: 0.0001). A total of 652 liquid biopsy samples reported by a MGPT (20 genes), were used for benchmarking. We performed Fisher's exact test (p<0.05) both at the variant and gene-based level to analyze the association between true and false positive predictions.
Results
In our study, we optimized the algorithm's execution time by implementing it in a parallel processing framework. We were able to calculate LoDs in 44.32 kb/min speed within the configuration of 64 cores and 256 GB of memory. Based on reported detectable variants, the algorithm significantly demonstrated 89.92% positive predictive value (p=0.0001). When we assessed the algorithm at the gene-based level, all of 20 cancer-related genes were found statistically significant (p<0.003), which proves our testing accuracy.
Conclusions
The algorithm achieved highly significant associations by overcoming the limitations of comparison-based LoD calculations, both at the variant- and gene-based levels. These findings highlight the potential of our tool to aid precision oncogenomics from liquid biopsy samples. Overall, the study presents a novel LoD tool for all NGS applications, particularly in the scope of MGPT for somatic variants. The tool holds promise in advancing precision oncogenomics and may serve as a valuable asset in all personalized treatment strategies.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
Acibadem Mehmet Ali Aydinlar University, Institute of Health Sciences, Department of Genome Studies.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
158P - Enhancing the communication of genomic results: Understanding patient and clinician perspectives
Presenter: Eleanor Johnston
Session: Cocktail & Poster Display session
Resources:
Abstract
159P - Precision medicine-based platform to guide the treatment of EML4-ALK fusion lung cancers and other NSCLC
Presenter: Nathan Merrill
Session: Cocktail & Poster Display session
Resources:
Abstract
160P - CICLADES-CE study: Genomic signatures detected in DNA from FFPE samples of patients with advanced or metastatic breast cancers treated with anti-aromatase and CDK4/6 inhibitors
Presenter: Margaux BETZ
Session: Cocktail & Poster Display session
Resources:
Abstract
161P - PDL1 expression and its relation to EML4-ALK gene variants in metastatic lung adenocarcinoma: A single-center real-world experience
Presenter: Santhosh Meedimale
Session: Cocktail & Poster Display session
Resources:
Abstract
163P - Impact of genomic sequencing data on treatment decisions in advanced breast cancer (ABC)
Presenter: Sviatoslav Chekhun
Session: Cocktail & Poster Display session
Resources:
Abstract
164P - Clinical utility of comprehensive molecular profiling tests for advanced gastrointestinal tumors
Presenter: Alexandra Lebedeva
Session: Cocktail & Poster Display session
Resources:
Abstract
165P - Evaluation of the mutational profile in patients with metastatic non-small cell lung carcinoma diagnosed in a tertiary hospital which was performed by NGS method
Presenter: Kankan Deka
Session: Cocktail & Poster Display session
Resources:
Abstract
166P - Targeted next-generation sequencing as reliable detection of genetic profile for cancer treatment to guide oncologists in Pakistan
Presenter: Zeeshan Ahmed
Session: Cocktail & Poster Display session
Resources:
Abstract
167P - Molecular analysis of gastrointestinal stromal tumor (GIST): The experience of Regina Elena National Cancer Institute
Presenter: Andrea Torchia
Session: Cocktail & Poster Display session
Resources:
Abstract
168P - Usefulness of liquid biopsy in the management of patients with advanced or metastatic pancreatic cancer
Presenter: Jorge Iranzo Barreira
Session: Cocktail & Poster Display session
Resources:
Abstract